Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

EP: 1.How Uveal Melanoma Differs from Cutaneous Melanoma

EP: 2.Common Symptoms of Uveal Melanoma and the Typical Diagnostic Journey of the Patient

EP: 3.Historic and Current Treatment Options for mUM

Now Viewing

EP: 4.Implications of Clinical Trial Data on Bispecific T-Cell Receptor Immunotherapy for mUM

EP: 5.Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM

EP: 6.An Expert’s Experience in Prescribing Tebentafusp and Other Therapies for mUM and a Commentary on Patient Education and Resources

EP: 7.Treatment Options for Patients with mUM Who Are Ineligible for Bispecific T-Cell Receptor Immunotherapy

EP: 8.Advice for Patients Living with Metastatic Uveal Melanoma

Related Videos

Related Content

Advertisement

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.

Related Content

Advertisement

July 12th 2021

KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

Jamie Cesanek

The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.